InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at Biotech Showcase
Dec 21, 2022
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that it will be presenting at the Biotech Showcase on Monday, Jan. 9, 2023. Tryp’s presentation is slated to begin at 11 a.m. PT at the Hilton San Francisco Union Square Hotel in San Francisco, California. Interested parties should visit https://ibn.fm/dEhHP to attend the event. In addition, Tryp’s CEO Jim Gilligan and CBO Peter Molloy will be in San Francisco from Jan. 8-11, 2023, during the 41st Annual J.P. Morgan Health Care Conference and will be available for meetings with investors as detailed in the announcement.
To view the full press release, visit https://ibn.fm/kxOvb
About Tryp Therapeutics Inc.
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The company has an ongoing phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida and an upcoming phase 2a clinical trial with the University of Michigan for the treatment of fibromyalgia, both of which are utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate efficacy in these indications. Where a preliminary clinical benefit has been demonstrated, subsequent studies are expected to utilize TRP-8803, which has the potential to further improve efficacy, safety and patient experience. For more information about the company, please visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork
More News
Strikes Put Saudi Arabia’s Economy Under Pressure
Deadly attacks on the main Saudi airport add to the challenges facing the country, as it seeks to maintain energy production and keep major events on track.
HMV to close Oxford Street store after three years
HMV says it is looking for a new site in London's West End, but its current site is "unviable".
How to avoid getting stung if you miss credit card payments
People are increasingly falling behind on credit card repayments, so here's the best way to get debt advice.
Healey faces £35bn Budget challenge to meet spending pledges, says think tank
The Institute for Fiscal Studies says the government will need a "top-up" of billions of pounds if it wants to meet its spending plans.
Campaigners claim minister attempting to undermine 'Holiday Hunger Bill'
The education minister has warned it would immediately cost his department £20m a year at a time when it is already struggling to balance its budget.
AI is less regulated than milk, says Microsoft president
Brad Smith calls for global rules on AI, and says the UK is in the "best position" to lead the charge.
Why some have no choice but to pay costly oil prices
The rural communities vulnerable to heating oil prices rises as the weather gets colder.
Documents falsified to evade tax on Abramovich's wealth, BBC finds
Backdated paperwork also made the Russian oligarch’s yachts and mansions disappear from accounts, investigation finds.
China's growth offers opportunity over shock, experts say
After four days touring the frontlines of China's economic evolution, from Xinyu, an age-old manufacturing hub reinventing itself with advanced industries, to the bustling entrepreneurial engine of Wenzhou, the cradle of the country's private sector, a group of former international political leaders and scholars converged in Beijing on Sunday for the Mingde Strategic Dialogue 2026.
Roofing scammers con homeowners out of thousands of pounds
One in 10 scams reported to Citizens Advice relate to fraudsters charging for work not done, or done badly.
Trump faces growing backlash over plans to import diesel from Russia
Both Republican and Democratic lawmakers have criticised the deal, which was announced weeks before the US midterm elections.
Citroen revives the 2CV for an electric age
The French firm is reinventing the classic model as carmakers come under pressure from Chinese rivals.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.